Swine influenza

Global Swine Influenza Clinical Trial Pipeline Landscape Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 6, 2023
Infectious Diseases, Health, Veterinary, Swine influenza, Vaccine, Meat

The "Global Swine Influenza Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Swine Influenza Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.
  • The report provides the most up-to-date information on key pipeline products within the global Swine Influenza market.
  • It covers emerging therapies for Swine Influenza in active clinical development stages including early and late stage clinical trials.
  • The report provides Swine Influenza pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Fluid Management Systems Market - Global Trajectory & Analytics to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 18, 2022
Other Manufacturing, Manufacturing, Swine influenza, Lists of countries and territories, Infection, Disposable product, Hospital, CAGR, Hepatitis A, Hospital-acquired infection, Viral hemorrhagic fever, Meningitis, HIV/AIDS, Immunodeficiency, STD, System, Zika virus, Fluid, Malaria, Growth, IV, Patient safety, Fever Dream, Tuberculosis, Vertically transmitted infection, Pet, Pharmaceutical industry

The "Fluid Management Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fluid Management Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • the global market for Fluid Management Systems estimated at US$11.1 Billion in the year 2022, is projected to reach a revised size of US$18.5 Billion by 2026, growing at a CAGR of 13.2% over the analysis period.
  • This segment currently accounts for a 32.5% share of the global Fluid Management Systems market.
  • The U.S. Market is Estimated at $3.6 Billion in 2022, While China is Forecast to Reach $2.4 Billion by 2026
    The Fluid Management Systems market in the U.S. is estimated at US$3.6 Billion in the year 2022.

HITN Wins 2021 Disruptors in Healthcare Sharecare Awards

Retrieved on: 
Tuesday, November 2, 2021
Film & Motion Pictures, Consumer, Entertainment, Hispanic, TV and Radio, Online, Haemophilus influenzae, COVID-19, Science, WXEL-TV, United States Digital Service, Associated Press, Technology, Apple TV, Swine influenza, Xfinity, Literacy Coalition of Palm Beach County, South Florida PBS, Organization, Virus, AP, General manager, Mediacom, Discovery Health Channel, SARS, DIRECTV, Associated, Â, New America Media, Charter Spectrum, Public broadcasting, Television, Treasure Coast, AT&T TV, AT, Lumen Technologies, Life, National Academy of Television Arts and Sciences, The National Academy, Board, CEO, Environment, NY, PBS, Weapons in Star Trek, News, Health, WPBT2, Association, Android, Dish Network, Virology, HITN, Prism, Culture, Education, AT&T, Verizon Fios, HIV, HITN-TV, South Florida PBS, AP, HITN-TV, SOUTH FLORIDA PBS, AP

Fauci: the Virus Hunter was recognized by the 2021 Sharecare Awards as a winner in the Disruptors in Healthcare category.

Key Points: 
  • Fauci: the Virus Hunter was recognized by the 2021 Sharecare Awards as a winner in the Disruptors in Healthcare category.
  • The Sharecare Awards, in association with The National Academy of Television Arts & Sciences, New York Chapter (NY NATAS), honors excellence in documentaries, series, shorts, web/online programming related to health and well-being.
  • The Associated Press and AP Productions are honored to have joined together with South Florida PBS and HITN to tell this impactful story.
  • Download the "HITN GO" Everywhere app available on Apple, Android, Apple TV, and Roku with a wired subscription.

GeneTex Develops Recombinant Influenza Nucleoprotein Antibodies as Potential Diagnostics

Retrieved on: 
Monday, August 2, 2021
Influenza, Articles, Health, Orthomyxoviridae, Animal virology, Pandemic, Influenza A virus subtype H3N2, Swine influenza

The Company has now expanded its existing influenza virus catalog with the release of a series of recombinant rabbit monoclonal antibodies that broadly detect the nucleoproteins (NPs) of influenza A and influenza B strains.

Key Points: 
  • The Company has now expanded its existing influenza virus catalog with the release of a series of recombinant rabbit monoclonal antibodies that broadly detect the nucleoproteins (NPs) of influenza A and influenza B strains.
  • Both influenza A and influenza B viruses are responsible for potentially lethal human disease and epidemics, with influenza A associated with pandemics.
  • There are three recombinant antibodies ( GTX636199 [HL1078] , GTX636247 [HL1089] , GTX636318 [HL1103] ) for influenza A NP and three ( GTX636099 [HL1068] , GTX636100 [HL1069] , GTX636194 [HL1073] ) for influenza B NP.
  • These recombinant influenza NP antibodies mark another milestone in GeneTex's efforts to support research combating pathogenic viruses, both endemic and emerging.

FDA Grants Emergency Use Authorization for New COVID-19, Flu A, Flu B Combo Kit

Retrieved on: 
Tuesday, February 16, 2021
Medical specialties, Medicine, Health, COVID-19 testing, Coronavirus disease, Influenza A virus subtype H1N1, Influenza, Live attenuated influenza vaccine, Seattle Coronavirus Assessment Network, Swine influenza

CARLSBAD, Calif., Feb. 16, 2021 /PRNewswire/ --The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit from Thermo Fisher Scientific, the company announced today.

Key Points: 
  • CARLSBAD, Calif., Feb. 16, 2021 /PRNewswire/ --The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit from Thermo Fisher Scientific, the company announced today.
  • The TaqPath COVID-19, Flu A, Flu B Combo Kit is a real-time PCR test for the detection and differentiation of RNA from the SARS-CoV2, influenza A and influenza B viruses in nasopharyngeal and nasal swabs.
  • The TaqPath COVID-19, Flu A, Flu B Combo Kit helps labs expand their existing COVID-19 testing menu for respiratory samples while maintaining low operational costs and workflow simplicity.
  • Testing with the TaqPath COVID-19, Flu A, Flu B Combo Kit is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C.

Guillain-Barré Experts Clarify COVID-19 Vaccine Confusion with Open Letter to Dr. A.S. Fauci

Retrieved on: 
Monday, December 21, 2020
Medical specialties, Medicine, Health, Vaccines, Influenza vaccines, Swine flu pandemic vaccine, Influenza vaccine, Swine influenza, Vaccine, COVID-19 vaccine, Influenza, Anthony Fauci

In response to a recent public statement made by Dr. A.S. Fauci, Director of NIAID, NIH, regarding the COVID-19 vaccine as it pertains to the GBS community, and to further clarify COVID-19 vaccine confusion among patients & caregivers, the following open letter to Dr. A.S.Fauci, has been authored as referenced.

Key Points: 
  • In response to a recent public statement made by Dr. A.S. Fauci, Director of NIAID, NIH, regarding the COVID-19 vaccine as it pertains to the GBS community, and to further clarify COVID-19 vaccine confusion among patients & caregivers, the following open letter to Dr. A.S.Fauci, has been authored as referenced.
  • "On the television show, you stated that people who had GBS in the past should avoid the COVID vaccines as they may cause another episode of GBS.
  • GBS was associated with the 1976/1977 swine flu vaccine at a rate of about 1 case/100,000 vaccinees.
  • In fact, the CDC recommends that everyone get the flu vaccine as the benefits of the vaccine outweigh the risks of GBS ( https://www.cdc.gov/vaccinesafety/concerns/guillain-barre-syndrome.html ).

Health Officials Stress Importance of Flu Vaccinations Amid the Rise in COVID-19 Cases During National Influenza Vaccination Week (December 6-13)

Retrieved on: 
Wednesday, December 9, 2020
Influenza, Medical specialties, Health, Medicine, Flu season, Seasonality, Influenza vaccine, Swine flu pandemic, Swine influenza

With the recent spike in COVID-19 cases, a severe flu season could mean dangerous, simultaneous respiratory infections that could overrun already stressed clinics and hospitals.

Key Points: 
  • With the recent spike in COVID-19 cases, a severe flu season could mean dangerous, simultaneous respiratory infections that could overrun already stressed clinics and hospitals.
  • "And this year, getting the flu shot is ever more critical as health officials work to avoid a dangerous and even deadly 'twindemic' of people getting the flu in addition to COVID-19."
  • Getting a flu vaccine has been shown to reduce the risk of getting sick, being hospitalized or dying from flu.
  • In 2019-2020, flu vaccination prevented an estimated 7.52 million illnesses, 3.69 million medical visits, 105,000 hospitalizations and 6,300 deaths due to influenza.

Global Influenza Vaccine Markets, 2020-2025 by Age Group, Vaccine Type, Valency, Distribution Channel, Geography and the Impact of Covid-19 with Ansoff Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 8, 2020
Health, General Health, Health, Articles, Animal virology, Influenza, Pandemic, Spanish flu, Orthomyxoviridae, Influenza A virus subtype H5N1, Swine influenza

The "Global Influenza Vaccine Market (2020-2025), By Age Group, Vaccine Type, Valency, Distribution Channel, Geography and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Influenza Vaccine Market (2020-2025), By Age Group, Vaccine Type, Valency, Distribution Channel, Geography and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Flu is a contagious respiratory illness caused by the influenza virus that affects the nose, throat, and sometimes the lungs.
  • Fever, cough, sore throat, runny or stuffy nose, muscle or body aches, headaches, fatigue are the common symptoms of the disease.
  • Influenza A virus is the only influenza virus known to cause flu pandemics, i.e., global epidemics of flu disease.

Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccine

Retrieved on: 
Thursday, November 19, 2020
Health, Medical specialties, Medicine, Vaccines, Influenza, Influenza vaccine, Animal virology, Live attenuated influenza vaccine, Vaccine, Swine influenza, Swine flu pandemic in the United States, Swine flu pandemic

Under the terms of the deal, Generex will receive an upfront payment of $2.5 million to initiate the Ii-Key vaccine development work to identify swine flu epitopes for a new Ii-Key vaccine.

Key Points: 
  • Under the terms of the deal, Generex will receive an upfront payment of $2.5 million to initiate the Ii-Key vaccine development work to identify swine flu epitopes for a new Ii-Key vaccine.
  • The current plan is to incorporate the Ii-Key-H1 vaccine into the seasonal influenza vaccine to create a Complete Vaccine across influenza strains.
  • Upon commercialization, Generex will receive a royalty on sales of the influenza vaccine.
  • Then, with the 2009 swine flu outbreak, Generex revitalized the Ii-Key vaccine program with the Ii-Key-H1 vaccine, using the H5 vaccine which is 100% homologous (the same) between the avian and swine influenza strains.

EmblemHealth Study Finds New Yorkers Overall More Likely to Seek Flu Vaccine This Year Amid COVID-19

Retrieved on: 
Monday, September 28, 2020
RTT, Medical specialties, Health, Influenza vaccine, Vaccines, Flu season, EmblemHealth, Influenza, Swine influenza

"The flu vaccination can help give New Yorkers peace of mind by reducing their likelihood of contracting the flu, which has similar symptoms to COVID-19 and can weaken their overall immune response to COVID-19 and other illnesses."

Key Points: 
  • "The flu vaccination can help give New Yorkers peace of mind by reducing their likelihood of contracting the flu, which has similar symptoms to COVID-19 and can weaken their overall immune response to COVID-19 and other illnesses."
  • Among New Yorkers who had not received the flu vaccination in the past three years, 80% said they still do not plan to get the flu vaccination this year.
  • EmblemHealth is working with our community and provider partners to provide critical education, outreach and access to New Yorkers this flu season.
  • As a market leader in value-based care, EmblemHealth partners with top doctors and hospitals to deliver quality, affordable care.